Key Takeaways
Novo Nordisk's fiscal year 2025 (calendar year ended December 31, 2025) marked the most challenging year in the company's modern history — not because of competitive failure, but because of the arithmetic of expectations. After four consecutive years of extraordinary growth driven by Ozempic (semaglutide injection for diabetes) and Wegovy (semaglutide for obesity), FY2025 revenue of approximately DKK 320-340B (approximately $46-49B USD) grew only approximately 10-14% versus the 25%+ growth rates of FY2022-FY2024, as the GLP-1 market matured from a supply-constrained hypergrowth phase to a competitive, insurance-access-dependent commercial execution challenge. The deceleration reflected three converging headwinds: Eli Lilly's tirzepatide (Mounjaro/Zepbound) gained substantial share in both diabetes and obesity markets as supply normalized; US Wegovy commercial access faced insurance coverage restriction from large PBMs and employer health plans implementing prior authorization policies; and international rollout of Wegovy proceeded more slowly than the company's original timeline as European reimbursement negotiations dragged. Diluted EPS (DKK) grew approximately 8-12%, a meaningful deceleration from the prior years' 30%+ growth, as margin pressure from Lilly competition on pricing and the investment in CagriSema (semaglutide + cagrilintide combination) development partially offset the continued high absolute gross margins of the semaglutide franchise (approximately 85%+). The FY2026 thesis is a pipeline optionality story: can CagriSema — a next-generation combination GLP-1 that showed approximately 22-25% body weight reduction in early trials versus Wegovy's approximately 15% — differentiate Novo Nordisk's obesity franchise from Lilly's tirzepatide and maintain global obesity market leadership through the next product cycle?
Novo Nordisk was founded in 1923 in Copenhagen, Denmark, through the merger of Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium — both insulin producers serving Europe's growing diabetic population. The company built its global diabetes franchise over a century on insulin products (Levemir, Tresiba, Fiasp) and GLP-1 receptor agonists (Victoza, Ozempic), becoming the world's largest diabetes drug company by revenue. The obesity strategy emerged from the observation that high-dose semaglutide produced dramatic weight loss in clinical trials designed primarily for diabetes — the same mechanism of action (GLP-1 receptor agonism, which reduces appetite and slows gastric emptying) produced weight loss as a primary rather than secondary endpoint. FDA approval of Wegovy in June 2021 and the subsequent explosion in demand for obesity pharmacotherapy — driven by clinical evidence, social media visibility, and the removal of the stigma around pharmaceutical obesity treatment — created the largest new pharmaceutical market in history. CEO Lars Fruergaard Jørgensen has managed the transition from diabetes specialist to the GLP-1 commercial platform company, including the significant manufacturing investment to address Wegovy supply shortages in 2022-2023.
Business Structure
Novo Nordisk reports two business segments.
Diabetes and Obesity Care (~DKK 300B, ~88% of total in FY2025): The core business comprising Ozempic (semaglutide weekly injection for Type 2 diabetes, ~DKK 120B+ revenue), Wegovy (semaglutide high-dose weekly injection for obesity, ~DKK 90B+ revenue), and older GLP-1/insulin products (Victoza, Rybelsus oral semaglutide, Levemir, Tresiba). Ozempic's Type 2 diabetes indication has maintained market leadership despite Mounjaro competition because Ozempic has a 5-year head start in physician familiarity and the lowest-dose presentation required for glycemic control. Wegovy's obesity indication is the higher-growth, higher-controversy component — higher-growth because the total addressable market for obesity is larger than diabetes; higher-controversy because insurance coverage, pricing at approximately $1,300/month list, and the social/political debate about pharmaceutical obesity treatment create commercial uncertainty.
Rare Disease (~DKK 40B, ~12%): Growth hormone therapies (Norditropin), hemophilia (Alhemo/concizumab), and rare endocrine conditions. This segment generates stable mid-single-digit growth and high margins, providing earnings diversification from the GLP-1 volatility.
Key Core Metrics Performance
Revenue and GLP-1 Franchise Growth (FY2021–FY2025)
| Fiscal Year | Total Revenue (DKK) | Ozempic Revenue | Wegovy Revenue | YoY Revenue Growth |
|---|---|---|---|---|
| FY2021 | DKK 140B | ~DKK 43B | ~DKK 3B | +18% |
| FY2022 | DKK 177B | ~DKK 68B | ~DKK 10B | +26% |
| FY2023 | DKK 232B | ~DKK 95B | ~DKK 31B | +31% |
| FY2024 | DKK 290B | ~DKK 110B | ~DKK 75B | +25% |
| FY2025 | ~DKK 330B | ~DKK 115B | ~DKK 95B | ~+14% |
The FY2025 deceleration from 25% to approximately 14% reflects Wegovy growth slowing as Lilly's Zepbound captured incremental new patients and Wegovy's commercial access limitations became apparent. Ozempic growth moderated as the Type 2 diabetes GLP-1 market matured.
Operating Margin and EPS (FY2021–FY2025)
| Fiscal Year | Revenue (DKK) | Operating Margin | Diluted EPS (DKK) | YoY EPS Growth |
|---|---|---|---|---|
| FY2021 | 140B | 42.5% | DKK 11.80 | +22% |
| FY2022 | 177B | 44.2% | DKK 16.09 | +36% |
| FY2023 | 232B | 45.1% | DKK 24.47 | +52% |
| FY2024 | 290B | 44.8% | DKK 34.00 | +39% |
| FY2025 | ~330B | ~43.5% | ~DKK 38.0 | ~+12% |
The operating margin slight compression in FY2025 reflects CagriSema development investment and the pricing competition with Lilly in obesity (PBMs demanding net price concessions as they gain leverage from a two-product market). The approximately 85%+ gross margin of semaglutide (minimal raw material cost; the active pharmaceutical ingredient is a peptide produced by biological synthesis) provides substantial structural margin protection.
US Wegovy Market Share and Access (FY2023–FY2025)
| Period | US GLP-1 Obesity Market | Wegovy Share | Zepbound Share | Covered Lives (Wegovy) |
|---|---|---|---|---|
| FY2023 | ~$8B | ~82% | ~18% (launched Dec 2023) | ~45% |
| FY2024 | ~$20B | ~55% | ~42% | ~50% |
| FY2025 | ~$30B | ~45% | ~50% | ~55% |
Lilly's Zepbound (tirzepatide for obesity, same molecule as Mounjaro) achieved rapid share capture from mid-2024 as supply normalized, leveraging tirzepatide's superior weight loss in head-to-head comparison trials (22% vs 15% body weight reduction) and Lilly's competitive net pricing strategy.
Market Evaluation
Novo Nordisk trades at approximately 15-22x forward earnings (adjusted to USD for comparison), reflecting the market's repricing from peak growth expectations to a more normalized growth company valuation. The bull case is CagriSema: the combination of semaglutide (GLP-1) plus cagrilintide (amylin analog) showed approximately 22-25% body weight reduction at 68 weeks in Phase 2 trials — meaningfully superior to Wegovy's 15% and competitive with Zepbound's best results. If Phase 3 CagriSema data replicate Phase 2 efficacy and the FDA approves by FY2027, Novo Nordisk re-establishes product leadership in obesity and extends the GLP-1 franchise for another 5-7 year cycle. The bear case is durable competitive pressure: Lilly's orforglipron (oral GLP-1, Phase 3) and its pipeline of next-generation obesity drugs keep Novo on a treadmill of constant pipeline investment; if tirzepatide achieves cardiovascular outcomes data equivalent to Wegovy's SELECT trial results, formulary preference by PBMs may shift permanently toward tirzepatide.
CagriSema Development and the Next-Generation GLP-1 Race
The next phase of the GLP-1 obesity market will be defined by combination therapies that target multiple metabolic pathways simultaneously — exploiting the observation that amylin, GIP, GLP-1, and glucagon receptors all play distinct roles in appetite regulation and metabolic signaling. Novo Nordisk's CagriSema pairs semaglutide (GLP-1) with cagrilintide (long-acting amylin analog that complements GLP-1 by acting on a separate satiety pathway). The Phase 2 REDEFINE trial data — published in early 2024 — showed 22.7% body weight reduction at 68 weeks, with the combination producing superior effects versus either agent alone. Critically, the side effect profile (nausea, vomiting) appeared manageable, avoiding the elevated GI adverse events that derailed some dual-agonist programs.
CagriSema's Phase 3 REDEFINE program entered full enrollment in FY2025, with data expected FY2026-FY2027. The development risk is that Phase 2 to Phase 3 translation in obesity has historically been imperfect — the Zepbound approval itself was based on Phase 3 data that significantly exceeded Phase 2 results, creating a template for optimism, but regulatory hurdles (particularly cardiovascular safety requirements) add complexity. If CagriSema Phase 3 shows 20%+ body weight reduction with acceptable safety in a large diverse trial population, it would be the first GLP-1 combination to meaningfully differentiate from semaglutide monotherapy in the regulatory and commercial package — re-establishing Novo Nordisk's product leadership heading into FY2028.